Pro Medicus is a Melbourne software company whose technology lets doctors view medical scans quickly. It has become one of the most valuable companies on the ASX. Here’s how it makes its money.
Pro Medicus is a health technology company based in Melbourne, and one of the most valuable technology companies on the ASX.
It was founded in 1983 by Sam Hupert and Anthony Hall, who still run the business as chief executive and technical director. Pro Medicus reports in Australian dollars, and its financial year ends on 30 June.
Visage
Its main product is Visage 7, software that lets radiologists view and analyse medical images such as MRI, CT and X-ray scans.
Modern scans create enormous files, and Visage is known for loading and displaying them very quickly, including over the internet from the cloud. That speed helps radiologists read more scans each day.
Most of Pro Medicus’s revenue comes from the U.S., where its customers include some of the country’s largest hospital systems and academic medical centres.
How it gets paid
Pro Medicus signs long-term contracts, typically five to 10 years, and is paid a fee each time a scan is read using its software, with guaranteed minimum payments. As hospitals carry out more scans, its revenue grows.
Once software is installed, adding more scans costs it very little. That means Pro Medicus keeps about three-quarters of its revenue as earnings before interest and tax, one of the highest margins of any company on the ASX.
It has no debt and pays out much of its profit as dividends.
Valuation and the risks
Because of its rapid growth and high margins, Pro Medicus’s shares trade at a very high price compared with its profits. That means even a small slowdown can cause big falls in its share price.
The risks include competition from bigger technology companies, delays in installing its software at new customers, its reliance on the U.S. market, and a stronger Australian dollar, which reduces the value of its U.S. earnings.
Latest results, as at 9 November 2026
Full year to June 2026, reported 18 August 2026: revenue rose 23 per cent to $261.7 million, and underlying profit rose 24 per cent to $144.7 million. Its earnings margin rose to 74.9 per cent. Without the impact of a stronger Australian dollar, profit would have grown about 32 per cent.
It signed 10 new contracts worth at least $407 million, including a 10-year, $170 million deal with UC Health in Colorado, and renewed all six contracts that were up for renewal. Pro Medicus paid total dividends of 69 cents a share, fully franked.
Next update: Pro Medicus reports its half-year results, to December 2026, in February 2027.























Comments
No comments yet. Start the conversation.